The Cole Eye Institute Retina Summit took place on Friday, May 5, 2017
This Summit provides a comprehensive medical and surgical update in new advancements in retinal imaging critical to enhance the accuracy of diagnosis and to improve treatment outcomes for diseases of the retina and vitreoretinal interface.
Promising Therapies in Development for DME: TIE-2 Activator, Integrin Peptide, Kallikrein Inhibition – Peter K. Kaiser, MD
Results from Recent Studies in Retinal Vein Occlusion – Rishi P. Singh, MD
Current and Future Therapies for Uveitis – Sunil K. Srivastava, MD
PANEL: Treating Retinal Vascular Disease – Rishi P. Singh, MD
Release Date: August 1, 2017
Expiration Date: August 1, 2018
This activity is intended to meet the needs of retina specialists, comprehensive ophthalmologists, retina fellows and healthcare providers who are interested in applying the most recent advancements in the retinal medicine field, including emerging techniques for imaging and treating retinal and vitreoretinal diseases.
Upon completion of this educational activity, participants should be able to:
Criteria for Success
In order to receive credit, participants should watch the entire video. Statements of credit will be awarded upon successful completion of the post test and online evaluation/claim credit form. If you have questions about this CME activity, please contact AKH Inc. at firstname.lastname@example.org.
CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Peter K. Kaiser, MD
Alcon, Allergan, Allegro, Aerpio, Bausch and Lomb, Bayer, Benitec, Biogen Idec, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside, Eyevensys, Ocunexus, Omeros, ONL, Regeneron, Novartis, Kanghong, Ophthotech, Ohr, Santen, SciFluor, Shire, Thrombogenics
Dante J. Pieramici, MD
Genentech, Regeneron, Allergan, Janssen, Ophthotec
Rishi P. Singh, MD
Genentech, Regeneron, Allergan
Genentech, Regeneron, Allergan, Apellis
Sunil K. Srivastava MD
Allergan, Santen, Sanofi, Regeneron, Zeiss, Bausch and Lomb
Dorothy Caputo, MA, BSN, RN – CE Director of Accreditations
-Nothing to disclose
MCME Global Staff and Planners
-Nothing to disclose
AKH Planners and Reviewers
-Nothing to disclose
This activity is supported by an educational grant from Alcon, Genentech and Regeneron.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
Please answer the following pre-question before moving on to the session presentation.